Results 191 to 200 of about 23,209 (275)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease

, 2017
WillianO Castillo, Andrés Felipe Aristizábal-Pachón   +1 more
openalex   +1 more source

Targeting cholinergic dysfunction in Alzheimer's disease: Development of next-generation galantamine derivatives. [PDF]

J Genet Eng Biotechnol
Keshavarz Z, Hassankhani A, Yoosefian M.
europepmc   +1 more source

Clinical effectiveness of galantamine in patients with cerebral infarction by 3D-DTI. [PDF]

Medicine (Baltimore)
Zhao H, Chen Z, Yang D.
europepmc   +1 more source

Selection of excipients for galantamine HBr orodispersible tablet through drug excipient compatibility study

, 2016
M Jeevitha, Vimal Pandey
openalex   +1 more source

Patterns and predictors of cholinesterase inhibitor use in dementia with Lewy bodies. [PDF]

Alzheimers Dement (N Y)
Heo RJ, Negida A, Wyman-Chick KA, Bateman JR, Rodriguez-Porcel F, Berman BD, Mukhopadhyay N, Barrett MJ.   +7 more
europepmc   +1 more source

Efficacy of medications in controlling cognitive dysfunction in Alzheimer's : a systematic review. [PDF]

Dement Neuropsychol
de Andrade SM, Rodrigues ÍSM, Rosa LMV, Taminato RL, Dos Santos GAA.   +4 more
europepmc   +1 more source

Computational Identification of Potent Multitarget Natural Ligands for Alzheimer's Disease Therapeutics. [PDF]

Scientifica (Cairo)
Sharif N, Bibi A, Sadiq R, Ullah I, Rauf A, Arshad MT, Bashir S, Zamir H, Gull S, Anwar T, Laryea E.   +10 more
europepmc   +1 more source

Persistence with anti-dementia medications: a systematic review and meta-analysis. [PDF]

Age Ageing
Sistanizad M, Peterson GM, Ling T, Salahudeen MS, Akondi VM, Bezabhe WM.   +5 more
europepmc   +1 more source